Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials

Table 1 Characteristics of included studies

Study	N	Patients	Treatment	MF	DFS HR(95%CI) DD vs Con	OS HR(95%CI) DD vs Con
Baldini 2003	150	IIIA/B	dd(CEF → CMF/CEF) CEF → CMF/CEF	5 years	0.77(0.47–1.26)	0.87(0.49–1.53)
CALGB 9741
(1)Citron 2003	2005	T0–3, N1–2, M0	dd(A → P → C) A → P → C dd(AC → P) AC → P	36 months	0.74(0.59–0.93)	0.69(050–0.93)
(2)Hudis 2005	2005	T0–3, N1–2, M0	dd(A → P → C) A → P → C dd(AC → P) AC → P	69 months	0.80(0.67–0.96)	0.85(0.68–1.05)
MIG-1
(1)Venturini 2005	1214	pN+(≤ 10); pN− and high risk	ddFEC FEC	10.4 years	0.88(0.71–1.08)	0.87(0.67–1.13)
(2)Giraudi 2016	1214	pN+(≤ 10); pN− and high risk	ddFEC FEC	15.8 years	0.90(0.77–1.05)	0.89(0.72–1.09)
GIM2	2091	pN+(≥ 1)	dd(EC → P) EC → P dd(FEC → P) FEC → P	7 years	0.77(0.65–0.92)	0.65(0.51–0.84)
Mastro 2015	2091	pN+(≥ 1)	dd(EC → P) EC → P dd(FEC → P) FEC → P	7 years	0.77(0.65–0.92)	0.65(0.51–0.84)
TACT2	4391	≥ 18 years; pN+; pN− and high risk (T0–3,N0–2,M0)	ddE → CMF E → CMF ddE → X E → X	85.6 months	NA	1.04(0.88–1.21)
Cameron 2017	4391	≥ 18 years; pN+; pN− and high risk (T0–3,N0–2,M0)	ddE → CMF E → CMF ddE → X E → X	85.6 months	NA	1.04(0.88–1.21)

N number of patients, MF median follow-up, DFS disease-free survival, OS overall survival, HR hazard ratio, CI confidence interval, DD dose-dense chemotherapy, Con conventional chemotherapy, NA not available, CEF cyclophosphamide + epirubicin + 5-fluorouracil; CMF, cyclophosphamide + methotrexate + 5-fluorouracil, A doxorubicin, P paclitaxel, C cyclophosphamide, AC doxorubicin + cyclophosphamide, FEC 5-fluorouracil + epirubicin + cyclophosphamide, X capecitabine

ISSN: 1477-7819